Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen, Obesity
New Obesity Drug MariTide Helps Patients Lose Up to 20% of Weight, Early Data Shows
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 percent of their weight in a year. The drug, MariTide, is given by injection once a month,
Amgen says obesity drug caused up to 20% weight loss after a year, with no plateau
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other experimental treatments.
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential rival to Wegovy and Zepbound.
2d
on MSN
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
15h
on MSN
Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger
Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.
pharmaphorum
3d
Amgen's big reveal of obesity data falls a bit flat
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
4d
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
FierceBiotech
4d
Amgen's monthly obesity drug matches competition in phase 2, but investors are unimpressed
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
4d
Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...
Investor's Business Daily on MSN
4d
Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity Treatment
Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback